2024
Pancreatic Cancer Surveillance and Survival of High-Risk Individuals
Blackford A, Canto M, Dbouk M, Hruban R, Katona B, Chak A, Brand R, Syngal S, Farrell J, Kastrinos F, Stoffel E, Rustgi A, Klein A, Kamel I, Fishman E, He J, Burkhart R, Shin E, Lennon A, Goggins M. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. JAMA Oncology 2024, 10: 1087-1096. PMID: 38959011, PMCID: PMC11223057, DOI: 10.1001/jamaoncol.2024.1930.Peer-Reviewed Original ResearchHigh-risk individualsSurveillance of high-risk individualsScreening programPancreatic ductal adenocarcinomaScreening high-risk individualsPancreatic cancer surveillanceUS academic medical centersPopulation-based screeningConditional logistic regressionUS national dataCox proportional hazards regressionAcademic medical centerLead-time biasProportional hazards regressionYear of diagnosisControl patientsRisk regression modelCancer surveillanceComparative cohort studyMain OutcomesComparison cohortOverall survivalCohort studyHazards regressionNational dataRisk of Pancreatitis After Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis
Magahis P, Chhoda A, Berzin T, Farrell J, Wright D, Rizvi A, Hanscom M, Carr-Locke D, Sampath K, Sharaiha R, Mahadev S. Risk of Pancreatitis After Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2024, 119: 2174-2186. PMID: 38976379, DOI: 10.14309/ajg.0000000000002942.Peer-Reviewed Original ResearchPancreatic cystic lesionsPancreatitis riskSystematic reviewEUS-TTNBRisk factorsCystic lesionsDerSimonian-Laird methodEnglish-language studiesEndoscopic ultrasound-guided fine-needle aspirationRandom-effects modelUltrasound-guided fine-needle aspirationRisk of post-procedure pancreatitisPredisposing characteristicsFine-needle-aspirationRisk of pancreatitisFine-needle aspirationPost-procedure pancreatitisLaird methodMeta-regressionSystematic searchPooled riskMeta-analyzedMeta-analysisPancreatitis eventsNeedle aspirationDisparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: a systematic review and meta-analysis
Silva-Santisteban A, Hernandez Woodbine M, Noriega M, Rabinowitz L, Grimshaw A, Farrell J, Chhoda A, Sawhney M. Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: a systematic review and meta-analysis. Gastrointestinal Endoscopy 2024, 100: 1-16.e20. PMID: 38432492, DOI: 10.1016/j.gie.2024.02.014.Peer-Reviewed Original ResearchCancer screening studyPopulation-based benchmarksPancreatic cancer screeningProportion of study participantsScreening studiesPancreatic cancer outcomesAge reportingInclusion of participantsMedian participant ageCancer screeningCancer outcomesStudy qualityWeb of Science Core CollectionNon-LatinoStudy participantsParticipant agePancreatic cancer studiesYear of publicationOvid MEDLINEGeneral populationSystematic reviewMeta-regressionSystematic searchScience Core CollectionOvid Embase
2023
Clinical predictive value of renalase in post-ERCP pancreatitis
Muniraj T, Desir G, Gorelick F, Guo X, Ciarleglio M, Deng Y, Jamidar P, Farrell J, Aslanian H, Laine L. Clinical predictive value of renalase in post-ERCP pancreatitis. Gastrointestinal Endoscopy 2023, 99: 822-825.e1. PMID: 38103747, DOI: 10.1016/j.gie.2023.12.020.Peer-Reviewed Original ResearchPost-ERCP pancreatitisRenalase levelsPlasma renalase levelsProspective cohort studyPotential clinical roleAcute experimental pancreatitisLongitudinal regression modelsPEP patientsPlasma renalaseCohort studyTertiary hospitalClinical roleExperimental pancreatitisRenalaseAbstractTextERCPPancreatitisFurther studiesAIMSRegression modelsS149 Can Pancreatic Cyst Detection Ratio Function as a Quality Indicator for EUS-Based Pancreatic Cancer Screening? A Systematic Review and Meta-Analysis
Chhoda A, Woodbine M, Silva-Santisteban A, Grimshaw A, Gunderson C, Farrell J, Sawhney M. S149 Can Pancreatic Cyst Detection Ratio Function as a Quality Indicator for EUS-Based Pancreatic Cancer Screening? A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2023, 118: s115-s116. DOI: 10.14309/01.ajg.0000950236.60039.42.Peer-Reviewed Original ResearchS119 Disparities in Race, Ethnicity, Sex, and Age Inclusion in Pancreatic Cancer Screening Studies: A Systematic Review and Meta-Analysis
Silva-Santisteban A, Chhoda A, Woodbine M, Rabinowitz L, Grimshaw A, Farrell J, Sawhney M. S119 Disparities in Race, Ethnicity, Sex, and Age Inclusion in Pancreatic Cancer Screening Studies: A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2023, 118: s95-s99. DOI: 10.14309/01.ajg.0000950116.35207.91.Peer-Reviewed Original ResearchSurveillance of Individuals at High Risk of Developing Pancreatic Cancer
Paiella S, Secchettin E, Lionetto G, Archibugi L, Azzolina D, Casciani F, Simeone D, Overbeek K, Goggins M, Farrell J, de Leon Pisani R, Tridenti M, Corciulo M, Malleo G, Arcidiacono P, Falconi M, Gregori D, Bassi C, Salvia R, Capurso G. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer. Annals Of Surgery 2023, 279: 37-44. PMID: 37681303, DOI: 10.1097/sla.0000000000006094.Peer-Reviewed Original ResearchConceptsPancreatic cancer surveillanceHigh-risk individualsCancer surveillancePancreatic cancerPooled prevalenceFinal diagnosisPancreatic cancer subjectsLow-grade dysplasiaDysplastic precursor lesionsNon-neoplastic conditionsPathogenic variant carriersPancreatic resectionSecondary outcomesPooled proportionSubgroup analysisTarget lesionsPrecursor lesionsSurveillance of individualsCancer subjectsVariant carriersEffect modifiersHigh riskHereditary predispositionSurgeryPathogenic variantsRacial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance.
Katona B, Klute K, Brand R, Everett J, Farrell J, Hawthorne K, Kaul V, Kupfer S, Paiella S, Simeone D, Sussman D, Zogopoulos G, Lucas A, Kastrinos F, Bi Y, Brentnall T, Chung D, Earl J, Gaddam S, Gallinger S, Graff J, Greenhalf W, Grossberg A, Hart P, Idos G, Jeter J, Lindberg J, Lowy A, Permuth J, Raitses-Gurevich M, Schrader I, Siveke J, Stoffel E, Vornhuelz M, Wadlow R. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Cancer Prevention Research 2023, 16: 343-352. PMID: 37259800, DOI: 10.1158/1940-6207.capr-22-0529.Peer-Reviewed Original ResearchConceptsHigh-risk individualsSex-based disparitiesPancreatic cancer surveillancePathogenic variantsPDAC surveillanceCancer surveillanceGuideline-based criteriaPancreatic cancer mortalityCommon age rangeRates of consentRace/ethnicityCancer criteriaRelated SpotlightMajority of participantsCancer mortalityHispanic ethnicitySurveillance studyDiverse patientsStudy participantsAge rangeTwo yearsSurveillanceEnrollmentEnrollment disparitiesParticipantsSa1408 PREDICTIVE VALUE OF RENALASE IN POST-ERCP PANCREATITIS
Muniraj T, Desir G, Gorelick F, Guo X, Ciarleglio M, Deng Y, Jamidar P, Farrell J, Aslanian H, Laine L. Sa1408 PREDICTIVE VALUE OF RENALASE IN POST-ERCP PANCREATITIS. Gastroenterology 2023, 164: s-384-s-385. DOI: 10.1016/s0016-5085(23)01894-2.Peer-Reviewed Original ResearchSu1423 ARE PANCREATIC CYSTS HIGH-YIELD IMAGING TARGETS DURING PANCREATIC CANCER SURVEILLANCE OF HIGH-RISK INDIVIDUALS? A SYSTEMATIC REVIEW AND META-ANALYSIS.
Woodbine M, Chhoda A, Silva-Santisteban A, Igbinedion S, Sur A, Germansky K, Farrell J, Sawhney M. Su1423 ARE PANCREATIC CYSTS HIGH-YIELD IMAGING TARGETS DURING PANCREATIC CANCER SURVEILLANCE OF HIGH-RISK INDIVIDUALS? A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2023, 164: s-607. DOI: 10.1016/s0016-5085(23)02416-2.Peer-Reviewed Original ResearchSurveillance of Pancreatic Cystic Neoplasms
Chhoda A, Schmidt J, Farrell J. Surveillance of Pancreatic Cystic Neoplasms. Gastrointestinal Endoscopy Clinics Of North America 2023, 33: 613-640. PMID: 37245939, DOI: 10.1016/j.giec.2023.03.010.Peer-Reviewed Original ResearchConceptsPancreatic cystic neoplasmsAdvanced neoplasiaCystic neoplasmsIntraductal papillary mucinous neoplasmClinical surveillance guidelinesHigh-risk morphologyConsensus clinical guidelinesPapillary mucinous neoplasmAccurate preoperative diagnosisCross-sectional imagingSurgical resectionSurgical indicationsPreoperative diagnosisSurveillance guidelinesSurveillance intervalsMucinous neoplasmsMalignant potentialClinical evaluationClinical guidelinesPancreatic cystsClinical challengeSurveillance strategiesNeoplasmsNeoplasiaCurrent conceptsUtility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms
Chhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan W, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood L, Iacobuzio-Donahue C, Wolfgang C, Kunstman J, Salem R, Farrell J, Ahuja N. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics 2023, 15: 28. PMID: 36803844, PMCID: PMC9942382, DOI: 10.1186/s13148-023-01429-5.Peer-Reviewed Original ResearchConceptsPapillary mucinous neoplasmMalignant risk stratificationCACNA1G geneRisk stratificationMucinous neoplasmsBiomarker panelBackgroundIntraductal papillary mucinous neoplasmIntraductal papillary mucinous neoplasmEarly detectionPrevious case-control studyHigh-grade dysplasiaCase-control studyPancreatic cancer precursorsReceiver Operating Characteristic (ROC) curve analysisSignificant diagnostic challengeCross-sectional imagingCharacteristic curve analysisOperating Characteristic curve analysisG geneHigh diagnostic specificityPrior validation studiesSignificant procedural riskIPMN tissuesSurgical resectionAdvanced neoplasiaRacial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance.
Klute K, Lucas A, Brand R, Everett J, Farrell J, Hawthorne K, Kaul V, Kupfer S, Paiella S, Simeone D, Sussman D, Zogopoulos G, Kastrinos F, Katona B, Consortium A. Racial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance. Journal Of Clinical Oncology 2023, 41: 687-687. DOI: 10.1200/jco.2023.41.4_suppl.687.Peer-Reviewed Original ResearchHigh-risk individualsSex-based disparitiesFamilial pancreatic cancerPDAC surveillancePancreatic cancer surveillancePeutz-Jeghers syndromeRates of consentSex-based differencesMedian ageAshkenazi Jewish ancestryMulticenter studyProspective studyCancer surveillancePancreatic cancerFamily historyLarge cohortMelanoma syndromeHereditary pancreatitisEarly detection researchStudy participantsEarly detectionStudy periodGermline DNACohortPDACPancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer.
Haimi I, Zogopoulos G, Dettwyler S, Everett J, Bi Y, Brand R, Chung D, Farrell J, Grossberg A, Kastrinos F, Katona B, Klute K, Kupfer S, Lucas A, Paiella S, Parmigiani G, Permuth J, Sears R, Sussman D, Simeone D, Consortium P. Pancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer. Journal Of Clinical Oncology 2023, 41: 689-689. DOI: 10.1200/jco.2023.41.4_suppl.689.Peer-Reviewed Original ResearchHigh-risk individualsPancreatic ductal adenocarcinomaPathogenic germline variantsFamilial pancreatic cancerCohort 1Worrisome featuresPancreatic cancerMain pancreatic duct diameterSolid massPancreatic duct diameterStandardized image acquisitionPGV groupGermline testingDuct stricturesIncurable stageMultiple cystsPancreatic abnormalitiesStandardized data collection systemNeuroendocrine tumorsDuctal adenocarcinomaCommon abnormalityFamily historyBenign lesionsLethal cancersPDAC riskPrecision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity?
Farrell J, Robert M, Lacy J. Precision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity? Clinical Gastroenterology And Hepatology 2023, 21: 2740-2742. PMID: 36640803, DOI: 10.1016/j.cgh.2022.12.033.Peer-Reviewed Original Research
2022
Reply to S. Raoof
Dbouk M, Katona B, Brand R, Chak A, Syngal S, Farrell J, Kastrinos F, Stoffel E, Canto M, Goggins M. Reply to S. Raoof. Journal Of Clinical Oncology 2022, 41: 1147-1149. PMID: 36315911, PMCID: PMC9928686, DOI: 10.1200/jco.22.01915.Peer-Reviewed Original ResearchSURVEILLANCE OF HIGH-RISK INDIVIDUALS LEADS TO LOWER STAGE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) AT DIAGNOSIS AND IMPROVED OVERALL AND DISEASE-SPECIFIC SURVIVAL
Blackford A, Canto M, Dbouk M, Kerdsirichairat T, Chak A, Brand R, Farrell J, Kastrinos F, Katona B, Rustgi A, Stoffel E, Syngal S, Klein A, Hruban R, Goggins M. SURVEILLANCE OF HIGH-RISK INDIVIDUALS LEADS TO LOWER STAGE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) AT DIAGNOSIS AND IMPROVED OVERALL AND DISEASE-SPECIFIC SURVIVAL. Gastrointestinal Endoscopy 2022, 95: ab544-ab545. DOI: 10.1016/j.gie.2022.04.1334.Peer-Reviewed Original ResearchThe PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.
Zogopoulos G, Bi Y, Brand R, Chung D, Earl J, Farrell J, Graff J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Permuth J, Sears R, Simeone D, Consortium T. The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer. Journal Of Clinical Oncology 2022, 40: e16239-e16239. DOI: 10.1200/jco.2022.40.16_suppl.e16239.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPathogenic germline variantsFamilial pancreatic cancerCancer predisposition genesCohort studyPancreatic cancerClinical dataAnnual surveillanceEffective early detection strategiesHigh-quality clinical dataHigh-risk premalignant lesionsModifiers of riskInternational cohort studyProspective cohort studyEarly-stage diseaseOverall survival rateEarly detection strategiesEarly-stage cancerBlood sample collectionRelevant clinical populationContribution of heritabilityPenetrance of diseaseQuality clinical dataParticipants ages 18Germline testing1061: PANCREATIC CANCER STAGE IN THE MULTICENTER CANCER OF THE PANCREAS SCREENING COHORT
Dbouk M, Chak A, Brand R, Farrell J, Kastrinos F, Katona B, Rustgi A, Kwon R, Stoffel E, Syngal S, Shin E, Canto M, Goggins M. 1061: PANCREATIC CANCER STAGE IN THE MULTICENTER CANCER OF THE PANCREAS SCREENING COHORT. Gastroenterology 2022, 162: s-242-s-243. DOI: 10.1016/s0016-5085(22)60577-8.Peer-Reviewed Original ResearchMo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
Chhoda A, Sharma A, Tang H, Tan W, Sailo B, Peters N, Ying L, Ruzgar N, Kunstman J, Salem R, Farrell J, Ahuja N. Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. Gastroenterology 2022, 162: s-708. DOI: 10.1016/s0016-5085(22)61664-0.Peer-Reviewed Original Research